Stonegate Capital Partners Initiates Coverage on Medicus Pharma, Highlighting Strategic Pipeline Expansion
Investment firm Stonegate Capital Partners has initiated coverage on Medicus Pharma Ltd., emphasizing the company's strategic acquisitions and partnerships that position it for growth in dermatology and infectious disease treatments.
Stonegate Capital Partners has initiated coverage on Medicus Pharma Ltd. (NASDAQ: MDCX), highlighting the company's strategic progress in building a diversified portfolio of clinical and pre-clinical assets. The coverage initiation comes as Medicus advanced several key initiatives in the second quarter of 2025, including the completion of its acquisition of Antev Limited, which expands the company's therapeutic pipeline into dermatology and infectious diseases.
The Antev acquisition complements Medicus' lead microneedle patch technology for skin cancer treatment, creating a more robust pipeline. Additionally, Medicus entered into a Memorandum of Understanding with Helix Nanotechnologies to co-develop thermostable vaccines for infectious diseases, a collaboration that addresses critical global healthcare challenges tied to cold-chain limitations. This partnership represents a significant step in overcoming vaccine distribution barriers in developing regions.
Financially, Medicus strengthened its position by securing an $8.0 million non-dilutive debenture financing, which extends the company's cash runway while minimizing dilution for existing shareholders. These strategic moves demonstrate Medicus' approach of combining organic development with opportunistic acquisitions to accelerate the advancement of its therapeutic assets. Further details on Stonegate's valuation methodology can be found in their comprehensive research report available at https://www.stonegatecp.com/research.
Medicus reported a net loss of $6.2 million in the second quarter of 2025, compared to $3.6 million in the same period last year, reflecting increased expenses of $4.6 million and research and development investment of $1.4 million. For the six-month period, the net loss widened to $11.3 million versus $5.3 million in the prior year, consistent with the company's expanded development and corporate activities. Despite these losses, cash and equivalents stood at $9.7 million at quarter-end, an increase from $4.2 million at year-end 2024.
The company's lead program, SkinJect, represents a innovative approach to skin cancer treatment. This dissolvable microneedle patch is designed for localized delivery of chemotherapeutic agents to treat non-melanoma skin cancers, including basal cell carcinoma. The product is intended for outpatient use, potentially reducing treatment costs and improving compliance relative to surgical and systemic approaches. Management expects that recent financings, combined with disciplined cost control, will provide sufficient capital to advance ongoing clinical and business development programs into 2026.
Stonegate Capital Partners employed a probability-adjusted Discounted Cash Flow model for their valuation, returning a range of $14.91 to $29.35 with a midpoint of $21.13. The valuation model uses a discount rate range of 17.50% to 22.50% and a current risk adjustment range of 50% to 40%. The firm notes that this model is highly leveraged to future years due to the long-term nature of Medicus' industry, creating potential for significant re-ratings as new information becomes available. Additional information about Stonegate's research services can be accessed at https://www.stonegatecp.com/services.